Conteúdo do texto
As we approach the start of the AEP selling season in October, I want to talk about what’s coming in 2026 for new and existing MAPD members.The Centers for Medicare & Medicaid Services have finalized the new rule, and really, it all comes down to three big themes—bringing down prescription drug costs, strengthening protections for beneficiaries, and holding plans more accountable.
Now, this isn’t happening in a vacuum. These changes continue to build on the Inflation Reduction Act, and together, they’re really reshaping how both Medicare Advantage and Part D plans operate.
So let’s start with Part D—because honestly, that’s where we’re seeing some of the biggest movement.
In 2026, prescription drug costs will be capped at $2,100 out of pocket for the year. What that means is more predictability—something seniors have been asking for, for a long time.
On top of that, the Medicare Prescription Payment Plan allows clients to spread those drug costs out over the year instead of getting hit with large upfront expenses. And moving into 2026, those who are already enrolled will automatically stay in the program, which just makes things easier and more consistent.
We’re also continuing to see the broader impact of the Inflation Reduction Act—things like manufacturer discounts, drug price negotiations, and a redesigned Part D structure are all playing a role here.
And importantly, some of the key protections remain in place—like the $35 insulin cap and $0 vaccines.
Now, let’s shift gears and talk about Medicare Advantage.
One of the biggest areas of focus here is prior authorization. CMS is stepping in to tighten things up—reducing inappropriate denials, requiring plans to honor approvals, and limiting those frustrating retroactive denials.
They’re also improving the appeals process and increasing transparency, so members have a clearer understanding of their rights and options.
For dual-eligible beneficiaries, we’re seeing better coordination between Medicare and Medicaid, more streamlined assessments, and in some cases, even a single ID card to simplify the experience.
And from a plan standpoint, payments to Medicare Advantage carriers are increasing by about 5% in 2026—which could help stabilize benefits, although we may still see some shifts in plan offerings.
So what does all of this mean in the real world?
For beneficiaries, it means more predictable drug costs and stronger protections—especially on the Medicare Advantage side.
But at the same time, there’s continued pressure on carriers, which could lead to changes in benefits or even plan exits in certain markets.
Now, for brokers—this is a huge opportunity.
Clients are overwhelmed right now. There’s a lot of change happening, and they’re looking for someone who can simplify it for them.
So lead with education. Help them understand what’s actually changing and what it means for their situation.
Focus on cost predictability—especially when it comes to Part D.
And most importantly, review plans carefully. Benefits, networks, and formularies could all shift in 2026.
At the end of the day, the brokers who truly understand these changes—and can communicate them clearly—are the ones who are going to build more trust and ultimately grow their business.
Because 2026 isn’t just another Medicare year… it’s really a continuation of a major transformation.
So stay informed, stay proactive, and position yourself as the expert your clients need.” As we move closer to AEP, We strongly encourage you to fully leverage the resources available through your partnership with EMG. Contact Scott Corner, Medicare Sales Advisor for EMG Brokers. scorner@emgbrokerage.com for more information.
Descrição do personagem
A youthful female wearing casual white top and black pants, ideal for product demonstrations or marketing events.
Ashley